CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells

Published:2015-05-14 Issue:3 Volume:151 Page:501-513
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Boulbes Delphine R.,Chauhan Gaurav B.,Jin Quanri,Bartholomeusz Chandra,Esteva Francisco J.

Funder

Breast Cancer Research Foundation

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-015-3414-3.pdf

Reference61 articles.

1. Jin Q, Esteva FJ (2008) Cross-talk between the ErbB/HER family and the type i insulin-like growth factor receptor signaling pathway in breast cancer. J Mammary Gland Biol Neoplas 13(4):485–498. doi: 10.1007/s10911-008-9107-3

2. Esteva FJ, Hortobagyi GN, Sahin AA, Smith TL, Chin DM, Liang SY, Pusztai L, Buzdar AU, Bacus SS (2001) Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry. Pathol Oncol Res 7(3):171–177

3. Esteva FJ, Sahin AA, Cristofanilli M, Arun B, Hortobagyi GN (2002) Molecular prognostic factors for breast cancer metastasis and survival. Semin Radiat Oncol 12(4):319–328

4. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785):177–182

5. Dawood S, Broglio K, Esteva FJ, Ibrahim NK, Kau SW, Islam R, Aldape KD, Yu TK, Hortobagyi GN, Gonzalez-Angulo AM (2008) Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol 19(7):1242–1248. doi: 10.1093/annonc/mdn036

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proteomic assessment of SKBR3/HER2+ breast cancer cellular response to Lapatinib and investigational Ipatasertib kinase inhibitors;Frontiers in Pharmacology;2024-08-29

2. Proteomic Assessment of SKBR3/HER2+ Breast Cancer Cellular Response to Lapatinib and Investigational Ipatasertib Kinase Inhibitors;2024-04-03

3. miRNAs as biomarkers of therapeutic response to HER2-targeted treatment in breast cancer: A systematic review;Biochemistry and Biophysics Reports;2024-03

4. Anchoring of hyaluronan glycocalyx to CD44 reduces sensitivity of HER2‐positive gastric cancer cells to trastuzumab;The FEBS Journal;2024-01-26

5. Liposome-enabled bufalin and doxorubicin combination therapy for trastuzumab-resistant breast cancer with a focus on cancer stem cells;Journal of Liposome Research;2024-01-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3